Scleroderma
Long term results show superiority of HSCT in severe scleroderma
Long-term follow-up of patients receiving hematopoietic stem cell transplantation (HSCT) for severe scleroderma has confirmed a durable survival benefit compared to conventional treatment with cyclophosphamide.
The findings, presented at the 2018 ACR/ARHP Annual Meeting in Chicago, extend the findings from...
Long-term follow-up of patients receiving hematopoietic stem cell transplantation (HSCT) for severe scleroderma has confirmed a durable survival benefit compared...